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Background: The SWI/SNF ATP dependent chromatin remodeling complex is a multi-subunit complex, conserved in
eukaryotic evolution that facilitates nucleosomal re-positioning relative to the DNA sequence. In recent years the SWI/SNF
complex has emerged to play a role in cancer development as various sub-units of the complex are found to be mutated
in a variety of tumors. One core-subunit of the complex, which has been well established as a tumor suppressor gene is
SMARCB1 (SNF5/INI1/BAF47). Mutation and inactivation of SMARCB1 have been identified as the underlying mechanism
leading to Malignant Rhabdoid Tumors (MRT) and Atypical Teratoid/Rhabdoid Tumors (AT/RT), two highly aggressive
forms of pediatric neoplasms.
Methods: We present a phosphoproteomic study of Smarcb1 dependent changes in signaling networks. The SILAC
(Stable Isotopic Labeling of Amino Acids in Cell Culture) protocol was used to quantify in an unbiased manner any
changes in the phosphoproteomic profile of Smarcb1 deficient murine rhabdoid tumor cell lines following Smarcb1
stable re-expression and under different serum conditions.
Results: This study illustrates broad changes in the regulation of multiple biological networks including cell cycle
progression, chromatin remodeling, cytoskeletal regulation and focal adhesion. Specifically, we identify Smarcb1
dependent changes in phosphorylation and expression of the EGF receptor, demonstrate downstream signaling and
show that inhibition of EGFR signaling specifically hinders the proliferation of Smarcb1 deficient cells.
Conclusions: These results support recent findings regarding the effectivity of EGFR inhibitors in hindering the
proliferation of human MRT cells and demonstrate that activation of EGFR signaling in Rhabdoid tumors is SMARCB1
dependent.
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The SWI/SNF ATP dependent chromatin remodeling com-
plex is a multi-subunit complex, conserved in eukaryotic
evolution, that facilitates nucleosome re-positioning relative
to the DNA sequence [1]. The SWI/SNF complex has been
found to play a role in fundamental cellular functions such
as transcriptional regulation, DNA replication and DNA
repair, but is mainly regarded to as a broad transcriptional
co-activator / co-repressor [2].* Correspondence: eden@vms.huji.ac.il
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demonstrated repeating mutations in sub-units of the
SWI/SNF complex across various types of tumors [3,
4]. One core-subunit of the complex, which has been
well established as a tumor suppressor gene is
SMARCB1 (SNF5/INI1/BAF47). As more and more
tumors are deep sequenced, mutations in SMARCB1
are found across a growing spectrum of cancers. More
specifically, inactivating mutations of SMARCB1 are
found in all Malignant Rhabdoid Tumors (MRT) and
Atypical Teratoid/Rhabdoid Tumors (AT/RT), two
highly aggressive forms of pediatric neoplasms [5]. In
spite of significant progress in treatment over recent
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to conventional chemotherapy and radiotherapy and
tumor resection is in many cases not possible [6, 7].
MRT which manifests in the kidney and AT/RT of the
central nervous system are unique in that apart from the
SMARCB1 locus they show unusually low mutation rate.
Several recent deep sequencing studies have revealed the
poor mutational landscape of these tumors [8–11]. This
finding suggests that SMARCB1 inactivation alters mul-
tiple pathways that promote cellular transformation, and
results in the simultaneous acquisition of the various
hallmarks of a transformed cancer cell [12] through a
singular mutation.
We have been studying SMARCB1 associated trans-
formation using cell lines derived from rhabdoid tumors
which developed in Smarcb1 heterozygous p53 null mice
[13]. These tumor cell lines show loss of heterozygosity
and lack Smarcb1. Restoration of Smarcb1 expression
had a minor effect on cell proliferation in culture but
completely ablated the tumorigenic capacity of xeno-
grafted tumor cells [14]. This result indicates that by
comparing the Smarcb1 deficient and proficient tumor
cells one can define Smarcb1 dependent changes which
are functionally relevant to transformation. Using this
system we previously showed that Smarcb1 deficiency
results in persistent AKT activation. Accordingly we
found that Smarcb1 deficient tumor cells are specifically
vulnerable to AKT or PI3-kinase inhibition [14].
In this study we use a high throughput phosphoproteo-
mic analysis comparing Smarcb1 deficient and proficient
tumor cells to further identify aberrant signaling associated
with Smarcb1 deficiency. We describe Smarcb1 dependent
constitutive phosphorylation of the EGFR, which is also
transcriptional elevated in Smarcb1 deficient cells and
demonstrate that inhibition of the EGFR/ERBB signaling
pathway inhibits proliferation of Smarcb1 deficient tumor
cells. We further identify multiple biological networks and
kinases whose regulation is altered in Smarcb1 deficient
tumor cells in a Smarcb1 dependent manner.Results
Profound changes in the phosphoproteomic landscape
between Smarcb1 proficient and deficient cells
We previously reported persistent activation of AKT
in Smarcb1 deficient cells [14], yet we could not
identify the cause of this Smarcb1 dependant activa-
tion. To better characterize altered signaling pathways
in Smarcb1 deficient tumor cells, which may contrib-
ute to the transformation process and to AKT activa-
tion, we conducted an unbiased quantitative phospho-
proteomic analysis designed to identify differentially
phosphorylated peptides between Smarcb1 proficient
and deficient tumor cells.The triple - SILAC (Stable Isotopic Labeling of Amino
Acids in Cell Culture) protocol [15–18] was used to com-
pare Smarcb1 deficient and proficient tumor cells (Cell
line 365 [14] containing an empty retroviral vector as con-
trol (pMIG) or pMIG-Smarcb1 respectively) (Fig. 1a, b).
Because serum is a rich source for signals, we expected
Smarcb1 dependent differential activation of signaling
pathways to reflect better under serum starvation condi-
tions, as demonstrated by the differential phosphorylation
of AKT (Fig. 1b, c and [14]).
All in all 10701 phosphorylation sites from 3655 dis-
tinct proteins were identified using high resolution mass
spectrometric analysis. 891 sites from 510 distinct pro-
teins were differentially phosphorylated in a statistically
significant manner between Smarcb1 deficient and profi-
cient cells under high serum, whilst under serum starva-
tion 616 sites from 407 distinct proteins demonstrated
differential phosphorylation (P-value < 0.05). Overall 205
residues from 134 distinct proteins exhibited a differen-
tial phosphorylation between Smarcb1 deficient and pro-
ficient cells regardless of the growth serum condition
(Fig. 1c, Additional file 1: Table S1 and Table S2).
Altered regulation of cell adhesion and cytoskeletal
organization in Smarcb1 deficient cells
Across all the mentioned sets a statistically significant
enrichment was found for proteins related to several GO
annotations including actin cytoskeleton and focal adhe-
sion (Fig. 2a). We previously profiled transcriptional
changes brought about following re-introduction of
Smarcb1 in the same tumor cell line and found enrich-
ment for cytoskeleton and focal adhesion categories
already at transcription level [14]. However, correlating
changes in phosphorylation levels with changes in levels
of expression (Fig. 2b) demonstrates that only a small
fraction of the changes in phosphorylation are correlated
to changes in gene expression, suggesting that altered
transcription accompanies altered regulation of these
cellular functions.
Proteins that demonstrate differential phosphorylation
between Smarcb1 proficient and deficient cells regard-
less of serum conditions include Paxillin (PAX) and its
binding protein Vinculin (VCL), two proteins localized
to focal adhesion sites. These genes were found to be
transcriptionally up-regulated in Smarcb1 proficient cells
[14]. PAX is found to be highly phosphorylated in
Smarcb1 proficient cells at residue Y118, whose phos-
phorylation is associated with altered cell adhesion,
motility and cytoskeletal organization [19]. Moreover,
Focal adhesion kinase 1 (FAK1) demonstrates elevated
levels of phosphorylation in Smarcb1 deficient cells at
serine 948, whilst FAK2 has elevated levels of phosphor-
ylation in Smarcb1 proficient cells at serine 375. Despite
the fact that the precise nature of the phosphorylation at
Fig. 1 Phosphoproteomic profiling reveals robust Smarcb1 dependent changes in protein phosphorylation. Matching Smarcb1 proficient and
deficient tumor cells were generated by re-introducing SMARCB1 (pMIG- Smarcb1) or an empty vector as control (pMIG) [14]. a The outline of
the phosphoproteomic study. Two triple-SILAC experiments were conducted. The first set allowed evaluation of Smarcb1 dependent changes
when cultured in normal serum whilst the second set allowed for the evaluation under serum starvation. Smarcb1 proficient cells grown in normal
serum and light isotopic labeling were included in both sets to allow comparison between the two sets. b Western blot demonstrating
differential AKT phosphorylation in Smarcb1 deficient versus proficient cells. Bar graph shows quantification of western blot presented
as fold change in AKT phosphorylation in pMIG/Smarcb1 cells normalized to beta-actin. c Volcano plot depicting Smarcb1 dependent changes in site
phosphorylation across the two sets. X-axis is the log2 ratio of the abundances of specific residues between Smarcb1 proficient and deficient cells.
Negative values for highly phosphorylated in Smarcb1 deficient cells. Y-axis is the logarithmic scale for the P-value of the fold change. For P.V < 0.05;
Violet dataset represents residues altered in high serum; Green dataset represents residues altered under serum starvation. d Venn-diagram portraying
the residues found to be differentially phosphorylated in a Smarcb1-dependent manner. Under 10 % serum, 458 residues are highly phosphorylated in
Smarcb1 proficient cells (In red) whilst 434 residues are highly phosphorylated in Smarcb1 deficient cells (In blue). Under low serum, 384 residues
(roughly two thirds) are highly phosphorylated in Smarcb1 proficient cells, whilst 233 residues are highly phosphorylated in Smarcb1 deficient cells.
Overall 205 residues are differentially phosphorylated between Smarcb1 proficient and deficient cells regardless of the serum conditions
Darr et al. Molecular Cancer  (2015) 14:167 Page 3 of 12the observed residues is unclear, these findings suggest
that loss of Smarcb1 leads to alteration in the compos-
ition and arrangement of focal adhesion sites and in the
organization of the cytoskeleton. These alterations can
be accompanied by deregulation of focal adhesion re-
lated signaling [20].
Indeed, actin staining reveals profound changes in
cytoskeletal organization between Smarcb1 proficient
and deficient cells. Whilst Smarcb1 proficient cells ex-
hibit actin stress fibers, Smarcb1 deficient cells lack
stress fibers and the actin seems diffused throughout the
cytoplasm (Fig. 3a). This Smarcb1 dependent remodeling
of the actin cytoskeleton was evident in an additional
Smarcb1 deficient murine MRT derived cell line; 167(Fig. 3a). Adhesion assay, which assesses adhesion fol-
lowing cell re-plating [21], showed that Smarcb1 defi-
cient cells adhere less efficiently than their Smarcb1
proficient counterparts (Fig. 3b), indicating a defect in
focal adhesion. In accordance with this last finding, Pax-
illin immunostaining reveals gross changes in adhesion
site size, number and appearance between Smarcb1 defi-
cient and proficient cells (Fig. 3c). Paxillin itself is mod-
erately accumulated in Smarcb1 proficient cells (Fig. 3d),
as expected in light of the transcriptional up-regulation.
All together, these results show that loss of Smarcb1 re-
sults in transcriptional and post-transcriptional deregu-
lation of processes related to the actin cytoskeleton and
to focal adhesion.
Fig. 2 GO annotation enrichment analysis of differentially
phosphorylated proteins. a Gene ontology (GO) annotations enrichment
among proteins found to be differentially phosphorylated between
SMARCB1 proficient and deficient cells. Evaluated using the David
Bioinformatics tool, x-axis indicates log base for Benjamini corrected
P-value. Violet dataset represents differentially phosphorylated
peptides in high serum; green dataset represents differentially
phosphorylated peptides in serum starvation. b Scatter plots
depicting Smarcb1 dependent differentially phosphorylated peptides
and their expression level in high or low serum. Negative values
denote highly expressed/phosphorylated in Smarcb1 deficient cells,
positive values denote highly expressed/phosphorylated in Smarcb1
proficient cells. Peptides corresponding to enriched GO categories
(from panel 2a) are highlighted in red. Group 1 includes GO
annotations: Cytoskeleton, Actin cytoskeleton and focal adhesion.
Group 2: Cell cycle. Group 3: Small GTPase regulator activity, protein
kinase activity and protein tyrosine kinase activity
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phosphoproteomic data
Differential phosphorylation profiles may reflect changes in
the activity of kinases and/or phosphatases between
Smarcb1 deficient and proficient cells. We therefore
attempted to determine whether targets of specific kinases
are over-represented in one condition over another. Using
the kinase target database from Phosphositeplus [22] we
constructed sets of known and characterized kinase targets
at residue level for each kinase and applied the GSEA algo-
rithm to test for enrichment of any such set in our phos-
phoproteomic data. Although the information linking
kinases to their target sites, particularly in mouse, is very
limited, this analysis identified the expected enrichment for
Cyclin dependent kinase (CDK1) targets and for AKT1 tar-
gets among residues that were phosphorylated in high
serum compared to serum starvation conditions in
Smarcb1 proficient cells (False Discovery Rate (FDR) = 0.05
for CDK1; FDR = 0.06 for AKT1). Application of the same
approach to the Smarcb1 dependent phosphorylation
under serum starvation revealed that peptides phosphory-
lated in Smarcb1 deficient tumor cells are enriched for tar-
gets of AKT, a result consistent with our previous findings
demonstrating activation of AKT in the same Smarcb1
deficient cell line used for the phosphoproteomic analysis.
This activation was found to persist in serum starvation
and result in phosphorylation of AKT targets such as ribo-
somal protein S6 [14]. Differentially phosphorylated Erk1/2
targets did not pass the statistical significance threshold as
individual peptides, but as a group, were significantly over-
represented among peptides that showed elevated phos-
phorylation in Smarcb1 deficient cells (Table 1). These
results are consistent with elevated phosphorylation of
ERK1/2 proteins at key residues in the Smarcb1 deficient
cells. (Y205 in ERK1 and T183 in ERK2 [23, 24]) in
Smarcb1 deficient cells under serum starvation found by
manual examination of the data.
Fig. 3 Differential morphology of Smarcb1 proficient and deficient cell lines. a Whilst in Smarcb1 proficient cell lines actin forms stress fibers across the
cell, in Smarcb1 deficient cell lines the actin is found diffused throughout the cytoplasm. In red – Phalloidin, In blue – Dapi b Reduced adhesiveness
of Smarcb1 deficient cell lines as evident in an adhesion assay. Cells were allowed to adhere for 20/40 min before quantification of adherent fraction
was carried out as described in the materials and methods section. T-test; 167 20', P.V = 0.0015; 167 40', P.V = 0.0027; 365 20', P.V = 0.0008; 365 40',
P.V = 0.0011. c Differential morphology, size and number of focal adhesion sites as visualized via Paxillin staining. In red – Paxillin, In blue – DAPI.
d Western blot showing a slight increase in PAX following Smarcb1 expression, consistent with available expression data
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additional kinases whose statistically significant differential
phosphorylation levels would suggest altered activation
state. These include activation of PKACA through phos-
phorylation of T198 [25] in Smarcb1 proficient cell lines
and phosphorylation in JNK1 Y185 [23, 24] and its targets
(Table 1) in Smarcb1 deficient cell lines (Additional file 1:
Table S1). Moreover, we find persistent phosphorylation
of EGFR Y1197 in Smarcb1 deficient cells. Tyrosine 1197
is an autophosphorylation site of the EGFR associated
with enzymatic activation.
Differential response to serum reveals altered regulation
of ErbB signaling in Smarcb1 deficient tumor cells
We next examined the differential response to serum
withdrawal between Smarcb1 proficient and deficient
cells. Phosphorylation sites that were regulated in a co-
ordinated manner in Smarcb1 deficient and proficient
cells upon serum withdrawal were excluded (Fig. 4a –
red dots). Of the remaining peptides, we focused on sites
whose phosphorylation level in response to serum with-
drawal was the most distinct between the Smarcb1 defi-
cient and proficient cells (Fig. 4a – in blue and gray).
The fact that few of the phosphorylation sites revealed
in the analysis had any known biological effect limited
our ability to deduce any functional significance fromthe data. Therefore, we focused on the affected proteins
and used STRING v9.1 [26] to explore protein neighbor-
hoods (high confidence physical and functional interac-
tions) and define functional protein association networks
which are differentially regulated between Smarcb1
proficient and deficient cells upon serum withdrawal (Add-
itional file 2: Figure S1). Several functional networks were
identified for proteins, which remain phosphorylated in
Smarcb1 deficient cells upon serum withdrawal but lose
their phosphorylation in Smarcb1 proficient cells (blue
group). These are enriched for proteins localized to the nu-
clear lumen and chromosome in addition to the cytoskel-
eton. More striking however is the enrichment in proteins
regulating cell cycle, transcriptional initiation and the ErbB
signaling pathway. In contrast, for proteins that lose phos-
phorylation specifically in Smarcb1 deficient cells upon
serum withdrawal (gray group), we find functional net-
works that are enriched for proteins localized to the nuclear
lumen and function in RNA splicing and processing (Fig. 4b
and Additional file 2: Figure S1). Cell cycle regulators in-
clude CDK1 which demonstrates differential phosphoryl-
ation of T14 related to cell cycle regulation. Chromatin
modifying proteins include ARID1A and SMARCC1
which together with SMARCB1 assemble to form the
SWI/SNF complex and regulate transcription. Proteins
annotated as ErbB signaling include ERK2, JUN MYC and
Table 1 Kinases for which phosphorylated target sites were found
enriched in Smarcb1 deficient cells. The table depicts kinases, their
target residues and relative abundances of the phosphorylated
peptide in SMARCB1 proficient/deficient cells (given as the log2
ratio). Kinase targets were defined as described in Materials and
methods section. Enrichment for targets was assessed using the
GSEA algorithm [53, 54]. Calculated Normalized Enrichment score
for kinase targets (KS test): ERK2 = 1.85; ERK1 = 1.66; AKT1 = 1.36;
JNK1 = 1.41. Calculated false discovery rate: ERK2 = 0.01;
ERK1 = 0.032; AKT1 = 0.223; JNK1 = 0.205
Kinase Target Residue Log2 (SMARCB1/pMIG)
Cdc25b S351 −1.12
Tsc2 S939 −1.65





























JNK1 Atf2 T53 −2.08
Jun S73 −2.76
Jun S63 −3.69
Fig. 4 Different response to serum withdrawal between Smarcb1
proficient and deficient cells. a Scatter plot depicting each peptides
response to serum withdrawal (N = 5518 peptides). X-axis: log 2 (high
serum/serum starvation) ratio of phosphopeptide abundance in
Smarcb1 proficient cells. Y-axis: log 2 (high serum / serum starvation)
ratio of phosphopeptide abundance in Smarcb1 deficient cells.
Red – correlated change for Smarcb1 proficient and deficient cells. Blue
and gray – anti-correlated peptides analyzed with STRING v9.1. b GO
annotation enrichment for networks identified using STRING v9.1. Colors
correlate to panel a. X-axis represents log base for Benjamini
corrected P-value
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residue S63 in JUN which are associated with induced en-
zymatic activity [23, 24], and residue T58 in MYC which isrequired for protein degradation [27], remain phosphory-
lated in Smarcb1 deficient cells upon serum withdrawal.
Upstream to these affects, EGFR is found to be highly
phosphorylated in Smarcb1 deficient cells deprived of
serum, in residue Y1197, an autophosphorylation site as-
sociated in humans with enzymatic activation of the re-
ceptor [28].
Differential EGFR expression and phosphorylation
promotes downstream AKT activation and cell
proliferation
We previously identified persistent activation of AKT in
Rhabdoid tumor cells which was Smarcb1 dependent and
central for proliferation and survival of Smarcb1 deficient
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pathways and part of the motivation for performing the
phospho-proteomic study was to identify the origin of
AKT activation. The phosphoproteomic analysis directly
indicated phosphorylation of EGFR in Smarcb1 deficient
cells, and the network analysis indicated EGFR pathway to
be activated in these cells. As activation of the EGFR and
ErbB signaling pathway lay upstream to all the above
mentioned signaling effects observed in Smarcb1 deficient
cell lines [29], we examined EGFR activation in Smarcb1
deficient cells.
Western blot analysis for an additional auto-
phosphorylation site of the EGFR, residue Y1092,
showed higher levels of phosphorylation in Smarcb1
deficient tumor cells compared with Smarcb1 proficient
cells under low serum. These results reinforce the obser-
vations made in the phosphoproteomic study and indicate
a Smarcb1 dependent activation of EGFR in tumor cells
(Fig. 5a).Fig. 5 Smarcb1 dependent EGFR phosphorylation and
transcriptional de-regulation. a Western blot demonstrating
constitutive phosphorylation of Tyr-1092 of the EGFR in Smarcb1
deficient cells, and down-regulation of the total-EGFR protein.
b Smarcb1 dependent transcriptional regulation of the ErbB family
receptors and the EGF ligand. Graph shows RNA levels relative to
beta actin as estimated by qRT-PCR. Note that the Y axis of the right
panel is two orders of magnitude lower, indicating that expression
levels of ErbB3, 4 and EGF are significantly low. In both cell lines Egfr
and ErbB3 showed reduced expression in Smarcb1 proficient cells. *
Fold change pMIG/Smarcb1 167 = 2.4, 365 = 4.5; T-test P.V; 167 =
0.00058, 365 = 0.0098. ** Fold change pMIG/Smarcb1 167 = 8.2, 365
= 6.8; T-test P.V; 167 = 0.0078, 365 = 0.013To address the origin of EGFR activation in Smarcb1
deficient tumor cells we considered various mechanisms
that can cause aberrant activation of EGFR and down-
stream signaling. We find total EGFR levels to be down-
regulated in Smarcb1 proficient cells, as evident in west-
ern blot (Fig. 5a). Transcriptionally, we find Egfr to be
significantly repressed in Smarcb1 proficient relative to
deficient cells (Fig. 5b). Examining the expression profile
of other ErbB family members we identify ErbB3 (HER3)
as an additional repressed target of SMARCB1 but the
significance of this result remains to be established since
ErbB3 levels are significantly lower than ErbB2 or Egfr
(Fig. 5b). Though expression data from MRT and AT/RT
tumors and cell lines suggests overexpression of ErbB2/
Her2 relative to other central nervous system tumors
[30, 31], in our system we detect no Smarcb1 dependent
change in the expression of ErbB2. ErbB4, as in most
cases [32], is not expressed and unresponsive to Smarcb1.
Egf itself is also transcriptionally unresponsive to Smarcb1
and with very low expression level. Two additional pro-
teins that negatively regulate EGFR (Caveolin1 [33–35]
and ERRFI1 [36]) are low in Smarcb1 deficient cells and
are upregulated upon its re-introduction, but expression
of either one of them in Smarcb1 deficient cells was insuf-
ficient in diminishing EGFR or AKT activation (Additional
file 2: Figure S2 and [14]).
We next inhibited EGFR using Gefitinib, a selective in-
hibitor of the EGFR kinase activity, or Lapatinib a dual
EGFR/ErbB2 kinase inhibitor [37]. Both treatments re-
sulted in inhibition of AKT phosphorylation, implicating
EGFR in the activation of AKT in these cells (Fig. 6a).
Surprisingly, though both treatments resulted in inhib-
ition of downstream AKT signaling, only Lapatinib treat-
ment led to reduction in EGFR phosphorylation while
Gefitinib treatment resulted in apparent elevation of
EGFR phosphorylation. These results repeated in mul-
tiple experiments and may relate to differences in the
preference of the molecules to altered conformations of
the EGFR kinase domain [38–41], and their possible ef-
fects on the protein stability which results in the accu-
mulation of the receptor [42]. Although the basis for
this paradoxical response of EGFR to Gefitinib is un-
clear, both inhibitors caused reduction of AKT phos-
phorylation, indicating that the ErbB pathway is
responsible for the persistent activation of AKT in
Smarcb1 deficient tumor cells.
Inhibition of EGFR signaling with Gefitinib or Lapatinib
reduced proliferation of Smarcb1 deficient tumor cells as
demonstrated by a WST1 proliferation assay. Importantly,
Smarcb1 deficient cells demonstrated greater sensitivity to
EGFR inhibitors, as their proliferation was hindered to a
greater extent than their Smarcb1 proficient counterparts
(Fig. 6b). These results implicate EGFR signaling in
Smarcb1 mediated tumorigenesis and suggest that Smarcb1
Fig. 6 EGFR activation mediates AKT activation in Smarcb1 deficient cells. a Inhibition of AKT activation upon treatment with the EGFR/HER2
inhibitor Lapatinib (Lap.) and the EGFR inhibitor Gefitinib (Gef.) versus the DMSO (D.) control. b WST1 proliferation assay demonstrating relative
proliferation of Smarcb1 deficient and proficient cells following a 6 day treatment with the EGFR inhibitors Lapatinib/Gefitinib, with the AKT
inhibitor 1/2, dual inhibition and serum withdrawal
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inhibition.Discussion
We previously showed that re-introduction of Smarcb1
diminishes the oncogenic capacity of Smarcb1 deficient
mouse rhabdoid tumors. By comparing Smarcb1 defi-
cient tumor cells with their Smarcb1 proficient counter-
parts we identified persistent activation of AKT in
Smarcb1 deficient cells, which plays a key role in the
survival and proliferation of these tumor cells [14]. To
elucidate the source of AKT phosphorylation in Smarcb1
deficient cells and to characterize Smarcb1 dependent ef-
fects on post-transcriptional regulation, we conducted a
comprehensive proteomic analysis of Smarcb1 dependent
changes in protein phosphorylation.
Smarcb1 deficiency affected the phosphorylation of many
proteins (Fig. 1). A systematic analysis of the phospho-
proteomic data indicated differential activation of multiple
kinases and pathways involved in regulation of cell survival
and proliferation (Table 1), which are generally in agree-
ment with our initial observation on persistent activation of
AKT in Smarcb1 deficient cells. Yet, the analysis of such
data at the phosphorylation site level is confined by the lim-
ited biological information available on many of the identi-
fied the phosphorylation sites, as a result the significance of
many intriguing observations remains to be explained (for
example: differential phosphorylation of various nuclear
pore complex proteins, centromeric proteins or lamins (see
supplementary tables and figures)).
Focusing on the differential response to serum star-
vation between Smarcb1 deficient and proficient cells,we identified several protein networks whose post-
transcriptional regulation is altered in Smarcb1 defi-
cient cells (Figs. 2, 4, Additional file 2: Figure S1).
The strong enrichment for cell cycle proteins among
proteins that remain phosphorylated following serum
withdrawal exclusively in Smarcb1 deficient cells
(Fig. 4), is in accordance with our findings on sus-
tained proliferation of Smarcb1 deficient cells cultured
under serum starvation [14].
Regardless of serum conditions, the analysis reveals
Smarcb1 dependent phosphorylation of actin cytoskel-
eton and of focal adhesion proteins. Correspondingly,
we find the actin skeleton of Smarcb1 deficient cells to
be diffuse and unstructured and lack stress fibers when
compared to Smarcb1 proficient cells, along with a gross
difference in the number, size and distribution of focal
adhesion sites (Fig. 3). Concurrently, Smarcb1 deficient
cells demonstrate an altered morphology and a reduced
adhesiveness which are consistent with the changes de-
scribed. Smarcb1 expression has been previously linked
to alterations in the regulation of cytoskeletal compo-
nents, migration and adhesion [43, 44].
The phosphoproteomic results suggested that in
Smarcb1 deficient tumor cells phosphorylation of ErbB
signaling cascade and EGFR itself persists even upon
serum withdrawal (Fig. 4 and Table 1). These results
were confirmed by western blot that demonstrated
higher EGFR phosphorylation specifically in Smarcb1
deficient cells (Fig. 5a). Accordingly, higher levels of total
EGFR correlating to transcriptional de-repression of Egfr
are observed in Smarcb1 deficient cells (Fig. 5b). These
findings suggest that EGFR activation is mediated by
transcriptional upregulation of the receptor. Moreover
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the ErbB3/HER3 receptor. This receptor is a kinase dead
receptor, incompetent in promoting downstream signal-
ing, yet heterodimers of ErbB2/HER2-ErbB3/HER3 have
a potent signaling competence observed in many neo-
plasms [32]. As such, this de-repression of ErbB3/HER3
in Smarcb1 deficient cells may be an additional mechan-
ism for ErbB downstream signaling in MRT and AT/RT.
Inhibition of EGFR kinase activity reduced AKT phos-
phorylation, indicating that it drives the activation of
AKT in Smarcb1 deficient cells. We further demonstrate
the effectiveness of selective EGFR signaling inhibitors
on the proliferation of Smarcb1 deficient cells, which
show increased sensitivity to Lapatinib and Gefitinib
compared to Smarcb1 proficient cells (Fig. 6). Several
studies in human Rhabdoid tumor cells have demon-
strated Lapatinib and Gefitinib as highly effective in in-
hibition of proliferation, consistent with high levels of
EGFR / ErbB expression and signaling [30, 45, 46].
Taken together, our results reproduce these findings and
reinforce the possibility of targeted EGFR/ErbB therapy
in MRT and AT/RT patients. Moreover, we demonstrate
that EGFR activation is a consequence of Smarcb1 defi-
ciency, suggesting that additional tumors with a muta-
tion in Smarcb1 or in other SWI/SNF subunits may be
susceptible to EGFR/ErbB inhibitors.
Oncogenic transformation is considered to occur through
a stepwise multiple-hit process, however several recent
studies that examined the genome of MRT and AT/RT
demonstrated exceptionally low mutation rates in both
neoplasms. Indeed, when analyzing point mutations, copy
number alterations or chromosomal rearrangements, all re-
current genetic aberrations were found to be limited to the
SMARCB1 locus [8–11]. Because SMARCB1 is a core com-
ponent of the SWI/SNF chromatin remodeling complexes
which function as transcriptional co-regulators, the low
mutation rate, together with the very early onset of these
tumors, raise the possibility that SMARCB1 inactivation
alone may be sufficient to drive multiple changes that pro-
mote cell transformation.
The networks we identify here and the experimental
findings from our system are in line with this intriguing
idea. This as they demonstrate how deficiency for
Smarcb1 results in profound transcriptional and post
transcriptional deregulation, which alter the cell's re-
sponse to external stimuli, its proliferative capacity and
the way it interacts with the environment, in so promot-
ing the acquisition of cancer hallmarks.
Conclusions
The results demonstrate activation of EGFR in Smarcb1
deficient murine rhabdoid cells lines which stems from
Smarcb1 dependent transcriptional de-repression of Egfr
and possibly ErbB3/HER3. Concurrently, downstreamactivation of the AKT and ERK signaling cascades is evi-
dent in the tumor cells, in line with our previous find-
ings. In accordance we find that small molecule EGFR
inhibitors (specifically Gefitinib and Lapatinib) hinder
the proliferation of Smarcb1 deficient rhabdoid cells and
may prove beneficial in clinical settings.
Materials and methods
Cell line establishment and culture
The establishment and characterization of Rhabdoid
tumor cell lines 167 and 365, as well as the re-
introduction of Smarcb1 was previously described [14].
Cells were grown in DMEM supplemented with 10 %
Hyclone fetal bovine serum (FBS), penicillin (50 mg/ml),
streptomycin (50 mg/ml), 2 mM L-Glutamine, 0.1 nM
non-essential amino acids, 0.1 mM β-Mercaptoethanol
and 1 mM sodium pyruvate. For serum starvation condi-
tions, cells were washed twice in PBS before being trans-
ferred to medium containing 0.1 % FBS. Gefitinib (Cell
signaling, Cat. No. #4765), Lapatinib (Santa Cruz, Cat.
No. sc-202205) and AKT inhibitor 1/2 (Calbiochem,
Darmstadt, Germany, AKT inhibitor VIII No. 124018)
were added in the indicated concentrations.
Growth curves
WST-1 (Roche, Cat. No. 11–644–807–001) reagent was
used with the standard protocol. Briefly, 1000 cells were
plated in triplicates in a 96-well plate and cultivated for
the indicated time. At each time point, 10 μl of WST-1
were added to 100 μl of growth medium and incubated
for an hour. Plate was read at 480 nm with the back-
ground absorbance at 690 nm.
Phosphoproteomic analysis
365 Smarcb1 proficient and 365 pMIG deficient cells
were SILAC labeled by culturing them for 10 population
doublings in SILAC-DMEM (deprived of lysine and ar-
ginine), supplemented with 10 % dialyzed FCS and
heavy, medium or light labeled lysine and arginine (lys0/
arg0; lys4/arg6; lys8/arg10). Following verification of
amino acid incorporation, during the experiments, cells
were transferred to the same SILAC culture medium,
supplemented with 10 % FCS or 0.1 % FCS over-night as
illustrated in Fig. 1a. Proteins were extracted using SDS
lysis buffer containing; 4 % SDS, 0.1 M DTT, 0.1 M
Tris–HCl pH 7.5. Trypsin digestion was performed fol-
lowing the FASP protocol [47] and was followed by
strong cation exchange and titanium-dioxide phospho-
peptide enrichment as previously described [48].
Mass spectrometric analysis was performed on the
EASY-nLC high performance liquid chromatography
coupled to the LTQ-Orbitrap Velos mass spectrom-
eter (Thermo Scientific), using data-dependent HCD
fragmentation of the top 10 peptides from each MS
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software and included phospho(STY) as a variable
modification. Data were filtered to have 1 % FDR on
the peptide and protein levels. Data analysis was per-
formed on the phospho(STY) sites table. Significance
B calculation (based on overall distribution of the
SILAC ratios and peptide intensity) was used to ex-
tract significantly changing phosphosites, with a p-
value threshold of 0.05.Network analysis
Proteins found to differentially respond to serum with-
drawal between v proficient and deficient cells were in-
putted to identify functional networks. Networks were
predicted using the String database [49] with a cut-off
for high confidence interactions (>0.9) based on co-
occurrence, co-expression, experiments and databases.
Resulting networks were visualized using the Cytoscape
platform [50].Kinase target enrichment analysis
We utilized the data available in the kinase target database
from Phosphositeplus [22] to define kinase target sets at
residue level, this for residues that are defined as phosphor-
ylated by a specific mouse kinase in mouse cells. We then
applied the GSEA algorithm to search for leading edge en-
richment of kinase target sets in the pre-ranked phospho-
proteomic data from Smarcb1 proficient versus deficient
cells under low serum or from Smarcb1 proficient cells
grown under high serum versus serum starvation.Protein extraction and Western blot analysis
proteins were extracted using a Triton based buffer
(0.5 % Triton, 300 mM Sucrose, 100 mM NaCl,
10 mM PIPES, 3 mM MgCl2*6H2O, 5 mM EDTA)
supplemented with 1 μM DTT, 1 μM PMSF, 1 μM
Pepstatin, 1 μg/ml Aprotenin, 0.5 μg/ml Leupeptin
and phosphatase inhibitor cocktail 2 (Sigma, Cat.
No. P5726). Following 10 min on ice the lysate was
centrifuged at 14,000 rpm and the pellet discarded.
Antibodies used for detection in western blot are as
follows: Anti-phospho EGFR Y1092 (Abcam, 1:1000
Cat. No. ab40815), Anti-EGFR (Abcam, 1:1000 Cat.
No. ab2430), anti-phospho AKT S473 (Cell signaling,
1:1000, Cat. No. 4058), Anti-AKT (Cell signaling,
1:1000, Cat. No. 11E7), anti-paxillin (Santa Cruz,
1:200, Cat. No. sc-136297), anti-beta-Actin (Abcam,
1:1000,Cat. No. ab6276), Strepavidin coupled HRP
(Jackson Immunoresearch Laboratories, 1:1000). Sec-
ondary antibodies coupled to horseradish peroxidase
(Jackson Immunoresearch Laboratories).Adhesion assay
As described in [21]. 80,000 cells from each cell line
were plated in a 24 well plate in triplicates and allowed
to adhere for the indicated time. The cells were then
gently washed and stained with 0.5 ml 0.1 % crystal vio-
let dissolved in 10 % acetic acid. The portion of the ad-
hered cells was extrapolated from a standard curve
prepared for each cell line concomitantly, where relative
fractions from 0 % – 100 % of 80,000 cells were plated
and allowed to adhere for several hours before staining.
Immunostaining
Cells were plated on 18 mm sterile coverslips and allowed
to adhere overnight. For Phalloidin cell were gently
washed in PBS++ before being fixed in 3.7 % paraformal-
dehyde (PF) in PBS for 10 min. Following fixation cells
were permeabilized in 0.5 % triton in PBS. Following
several washed coverslips were stained with the Texas-Red-
phalloidin (Invitrogen, 0.5U/ml, Cat. No. T7471) and DAPI
(Roche, 6 μg/ml, Cat. No. 10–236–276–001) for two hours
before being mounted on slides with vecta-shield. For Paxil-
lin immunostaining, permeabilization with 0.5 % triton in
3.7 % PF in PBS with 5 % sucrose for 5 min preceded
fixation for 25 min in 3.7 % PF in PBS. Following several
washes and blocking with 10 % FCS in PBS for an hour,
coverslips were stained with anti-paxillin (Santa Cruz,
1:200, Cat. No. sc-136297) followed by fluorescent second-
ary (Jackson Immunoresearch Laboratories) and DAPI
before being mounted. Images were collected on a Nikon
TE-2000 (Nikon, Melville, NY, USA) inverted microscope
and processed using NIS-elements software (Nikon). Iden-
tical camera and microscope settings were employed to
allow valid comparison between images of Smarcb1 defi-
cient and proficient cells.
RNA extraction, reverse transcription and real-time PCR
All performed using standard techniques and kits as de-
scribed in [51]. Primers used for expression analysis are
as follows: Egfr; F': ACACTGCTGGTGTTGCTGAC R':
TTGGGTGAGCCTGTTACTTG Erbb2; F': GCAGTGA
TCATCATGGAGCTG R': AGGTGGGTCTCAGGACT
GG Erbb3; F': GTGCTGGGTTTCCTTCTCAG R': TC
TGGTACTGGTTGTCAGCATC Erbb4; F': GACTTGC
CAAAAATGAAGCTG R': TGCTGTTCCAGGTCAGA
GAG Egf; F': CAAACGCCGAAGACTTATCC R': TTT
GGCCAGTCCTCTTGTTC Errf1; F': AGCGAGCAGA
GAGAAAGAGC R': ACTCTGGGATGCCTTCAAAT
Beta-Actin; F': TTTTGTGTCTTGATAGTTCGCCA R':
GCCGTTGTCGACGACCAG
Errfi1 cloning
The MS2-HBTH Biotin tag was cloned by PCR from the
pQCPX MS2-HBTH vector, generously provided by M.
Waterman [52], using the primers: F': ACTGGCT
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AGCATCCGCGGCCGCGCATG. The PCR product was
restricted with NheI and ligated into the SpeI site in the
pSIN-EF2-Nanog vector, which was formerly restricted
with BamHI and self-ligated in-order to excise Nanog.
The MS2-HBTH biotin tag was subsequently cloned
from the pSin EF2-MS2-HBTH constructed backbone
plasmid using the primers: F': ACTGGTCGACCAT
CATCACCACCATCATGAC and R': ACTGCTCGAG
CTCATTAATGATGGTGGTGATG. The PCR product
was restricted with SalI and XbaI and inserted into the
pHAGE retroviral vector restricted with SalI.
cDNA from SMARCB1 proficent 167 cell line was
used to PCR amplify Errfi1 transcript using the following
primers; F': ATGCGCGGCCGCATGTCAACAGCAGG
AGTTGC R': ATGCGTCGACTGGAGAAACCACGTA
GGATAA. The resulting amplicon was inserted into the
pHAGE-HBTH vector (described previously) between
the Not1 and Sal1 restriction sites. The resulting plasmid
was sequenced to ensure correct amplification and inser-
tion. For generation of viral vectors, plasmids were co-
transfected with VSVG and PHR into 293 T cells using
the jetPEI® transfection reagent (Polyplus, CA, USA). In-
fections were carried out for 2 sequential days with
8 μg/ml Polybrene followed by selection with Blasticidin.
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